Task Group Charge

To identify factors contributing to variation in access to and delivery of recommended lung nodule management, staging, and receipt of curative-intent surgery and radiation/SBRT for early-stage NSCLC, access to and use of  comphrehensive biomarker testing for targeted therapies, and strategies to overcome the factors contributing to this variation.

Leadership

Gerard A. Silvestri, MD, MS

Task Group Chair
Steering Committee Member
Medical University of South Carolina

Farhood Farjah, MD, MPH

Task Group Vice Chair
University of Washington

Task Group Members

Brett Bade, MD
Yale University

Upal Basu Roy, PhD, MPH
LUNGevity Foundation

Leigh Boehmer, PharmD, BCOP
Association of Community Cancer Centers

Elizabeth David, MD, MAS
University of Southern California

Jordan Garst
ALK Positive Outreach

Louise M. Henderson, PhD, MSPH
University of North Carolina at Chapel Hill

James Jett, MD
National Jewish Health

Bruce Johnson, MD
Dana-Farber Cancer Institute

Edward Kim, MD
Levine Cancer Institute

Jennifer King, PhD
GO2  Foundation for Lung Cancer

Linda Martin, MD, MPH
University of Virginia

Nikki Martin, MA
LUNGevity Foundation

Rhonda Meckstroth
ALK Positive Outreach

Raymond Osarogiagbon, MBBS
Baptist Memorial Healthcare

Shetal Patel, MD, PhD
University of North Carolina at Chapel Hill

Gregory Riely, MD, PhD
Memorial Sloan Kettering Cancer Center

M. Patricia Rivera, MD
University of North Carolina at Chapel Hill

Albert Rizzo, MD
American Lung Association

Liora Sahar, PhD, GISP
American Cancer Society

Helmneh Sineshaw, MD, MPH
American Cancer Society

Robert Suh, MD
University of California, Los Angeles

Douglas Wood, MD
University of Washington

(*) indicates Steering Committee member

Opportunities For Intervention/Influence:

  • Address the lack of experience and/or expertise in screen-detected lung nodule management
  • Identify strategies to reduce the variation (geographic, SES, income, race/ethnicity, rural, etc.) in access to lung cancer specialists
  • Identify strategies to overcome the non-adherence with staging and management guidelines
  • Highlight the disparities in receipt of curative-intent surgery for early stage NSCLC and develop strategies to eliminate these disparities
  • Develop strategies to reduce the variability in access and use of comprehensive biomarker testing for expression of immune-markers and targeted therapy